Vaxart's Oral Norovirus Vaccine Shows Promising Immunity Transfer to Infants
Event summary
- Vaxart published Phase 1 trial data showing its oral bivalent norovirus vaccine induced norovirus-specific antibodies in breastmilk and serum of lactating women, with passive transfer to infants via breastfeeding.
- The study, funded in part by the Bill & Melinda Gates Foundation, enrolled 76 women in South Africa and demonstrated a positive correlation between breast milk IgA and infant stool IgA.
- Vaxart's vaccine was safe and well-tolerated, with elevated antibody levels maintained through day 180 in the high-dose group.
- The company plans to initiate the next clinical trial in 2026, pending partnership or funding.
The big picture
Vaxart's data suggests a novel approach to conferring mucosal immunity to infants through maternal vaccination, addressing a significant unmet need in pediatric infectious disease. Norovirus imposes a substantial economic and health burden, with 21 million cases annually in the U.S. alone. The company's proprietary oral vaccine platform could position it as a key player in the infectious disease space if it can successfully navigate the regulatory and funding challenges ahead.
What we're watching
- Clinical Progression
- Whether Vaxart can secure the necessary funding or partnerships to advance its norovirus vaccine into later-stage clinical trials.
- Market Potential
- The pace at which Vaxart can demonstrate the efficacy of its oral vaccine in protecting vulnerable populations, particularly in under-resourced areas.
- Competitive Landscape
- How Vaxart's oral vaccine technology compares to other norovirus vaccine candidates in development, given the lack of approved vaccines for this disease.
Related topics